Controversy Over Hubei’s Final Drug Tender Prices
This article was originally published in PharmAsia News
Executive Summary
A Hubei FDA announcement that a tender for a 25 mg antibody fusion protein lyophilized powder came in about RMB 50 above the original tender price has triggered controversy.